Shanghai Shenqi Pharmaceutical Investment Management Past Earnings Performance
Past criteria checks 1/6
Shanghai Shenqi Pharmaceutical Investment Management has been growing earnings at an average annual rate of 24.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 5% per year. Shanghai Shenqi Pharmaceutical Investment Management's return on equity is 2.1%, and it has net margins of 2.3%.
Key information
24.5%
Earnings growth rate
24.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 5.0% |
| Return on equity | 2.1% |
| Net Margin | 2.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shanghai Shenqi Pharmaceutical Investment Management makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,194 | 50 | 876 | 33 |
| 30 Jun 24 | 2,246 | 60 | 885 | 36 |
| 31 Mar 24 | 2,333 | 57 | 966 | 22 |
| 31 Dec 23 | 2,341 | 57 | 983 | 32 |
| 30 Sep 23 | 2,386 | 59 | 1,047 | 41 |
| 30 Jun 23 | 2,392 | 51 | 1,082 | 49 |
| 31 Mar 23 | 2,383 | 49 | 1,076 | 59 |
| 31 Dec 22 | 2,389 | 49 | 1,102 | 46 |
| 30 Sep 22 | 2,313 | 72 | 1,097 | 59 |
| 30 Jun 22 | 2,350 | 57 | 1,198 | 52 |
| 31 Mar 22 | 2,338 | 71 | 1,222 | 47 |
| 31 Dec 21 | 2,303 | 70 | 1,216 | 51 |
| 30 Sep 21 | 2,193 | -141 | 1,359 | 44 |
| 30 Jun 21 | 2,135 | -325 | 1,306 | 46 |
| 31 Mar 21 | 2,029 | -328 | 1,247 | 50 |
| 31 Dec 20 | 1,819 | -341 | 1,119 | 43 |
| 30 Sep 20 | 1,836 | -145 | 986 | 28 |
| 30 Jun 20 | 1,856 | 55 | 951 | 22 |
| 31 Mar 20 | 1,844 | 69 | 949 | 21 |
| 31 Dec 19 | 1,928 | 84 | 1,010 | 20 |
| 30 Sep 19 | 1,980 | 124 | 1,036 | 27 |
| 30 Jun 19 | 1,907 | 105 | 1,003 | 28 |
| 31 Mar 19 | 1,934 | 100 | 999 | 23 |
| 31 Dec 18 | 1,853 | 106 | 948 | 23 |
| 30 Sep 18 | 1,883 | 114 | 918 | 27 |
| 30 Jun 18 | 1,894 | 137 | 916 | 31 |
| 31 Mar 18 | 1,772 | 138 | 870 | 25 |
| 31 Dec 17 | 1,736 | 130 | 849 | 24 |
| 30 Sep 17 | 1,762 | 165 | 861 | 13 |
| 30 Jun 17 | 1,650 | 164 | 827 | 0 |
| 31 Mar 17 | 1,657 | 166 | 848 | 0 |
| 31 Dec 16 | 1,598 | 182 | 832 | 0 |
| 30 Sep 16 | 1,592 | 168 | 845 | 0 |
| 30 Jun 16 | 1,604 | 192 | 854 | 0 |
| 31 Mar 16 | 1,553 | 207 | 842 | 0 |
| 31 Dec 15 | 1,593 | 217 | 895 | 0 |
| 30 Sep 15 | 1,400 | 192 | 828 | 0 |
| 30 Jun 15 | 1,381 | 187 | 826 | 0 |
| 31 Mar 15 | 1,331 | 199 | 798 | 0 |
| 31 Dec 14 | 1,294 | 180 | 785 | 0 |
| 30 Sep 14 | 1,286 | 188 | 735 | 0 |
| 30 Jun 14 | 1,225 | 161 | 724 | 0 |
| 31 Mar 14 | 1,079 | 124 | 640 | 0 |
| 31 Dec 13 | 929 | 112 | 534 | 0 |
Quality Earnings: 600613 has a large one-off loss of CN¥43.4M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 600613's current net profit margins (2.3%) are lower than last year (2.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600613's earnings have grown significantly by 24.5% per year over the past 5 years.
Accelerating Growth: 600613's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 600613 had negative earnings growth (-14.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 600613's Return on Equity (2.1%) is considered low.